When: Thursday, March 13, 2014 from 12:30 PM to 2:00 PM (EDT)
Join this upcoming webinar, to be held during Brain Awareness Week 2014, to discuss the latest market data and news in the digital brain health and brain training space, including Rosetta Stone’s acquisition of Vivity Labs (developer of Fit Brains mobile cognitive games), Bayer’s global partnership with CogniFit Read the rest of this entry »
Time for SharpBrains’ May 2013 e-newsletter, which features a variety of articles offering a more optimistic and evidence-based approach to brain and mental health than current practices.
First of all, let us highlight that Scientific American just published an excellent review of our new book. The author sums it up by saying that “…I wish I had read this awesome guide when I was much younger…I find the emerging field of neuroplasticity immensely exciting, and guides like this one are both hopeful and reasonable.” As a reader points out, the word “awesome” does not appear often in science-oriented publications…so we are especially proud to see the book merit such treatment.
That’s it for now. Have a stimulating June!
Mental exercises may prevent mental decline in seniors (CBC News): “A review released by the Canadian Medical Association Journal on the prevention of cognitive decline said that medicinal and non-medicinal products, and physical exercise did nothing to prevent the decline in healthy seniors, but mental exercises Read the rest of this entry »
Drugs for Early-Stage Alzheimer’s (good New York Times editorial):
“The Food and Drug Administration has proposed lowering the bar for approving drugs to treat people at the earliest stages of Alzheimer’s disease, before they have developed any serious impairment or overt dementia. The goal is commendable — to find ways to prevent or slow the progression of this terrible disease before it can rob people of their mental capacities. But the proposal raises troubling questions as to whether the agency would end up approving drugs that provide little or no clinical benefit yet Read the rest of this entry »
According to a new position statement by the American Academy of Neurology (AAN), prescribing cognitive enhancement, “attention-boosting,” drugs to healthy children is misguided and not justifiable. Interestingly, a 2009 position statement by AAN still in force today stated that doing so with adult “patients” is both legal and ethical (including the remark that “Neurologists who prescribe medications for the off-label use of neuroenhancement are acting lawfully,” without really challenging whether the drugs have been proven to be a) effective and b) safe in that context). Read the rest of this entry »
By: Dr. Pascale Michelon
According to a new study, the population with Alzheimer’s Disease in the US will triple by 2050: from 4.7 millions in 2010 to 13.8 millions. This emphasizes the urgent need for more research to find preventive measures, and for more enlightened public health initiatives and individual lifestyles designed to decrease dementia risks and delay onset of symptoms.
Between 1993 and 2011, researchers followed more than 10,000 individuals 65 and older. Participants were interviewed and assessed for dementia every three years. Read the rest of this entry »
Summary of the report just issued by The Royal Society in the UK: “Although the impact of human enhancement technologies has been widely debated, until now they have not been considered in terms of their impact upon the nature of work…the Academy of Medical Sciences, British Academy, Royal Academy of Engineering and Royal Society came together to Read the rest of this entry »